Journal: eLife

Article Title: Endothelial cell signature in muscle stem cells validated by VEGFA-FLT1-AKT1 axis promoting survival of muscle stem cell

doi: 10.7554/eLife.73592

Figure Lengend Snippet:

Article Snippet: Chemical compound, drug , Bovine serum albumin (BSA) , Jackson Immuno Research , 10001620 , FACS/Immunostaining (1–2%).

Techniques: Plasmid Preparation, RNAscope, Sequencing, Imaging, Staining, Crystal Violet Assay, Viability Assay, cDNA Synthesis, Isolation, DNA Extraction, Western Blot, Extraction, Protein Extraction, Modification, Recombinant, Transfection, Infection, Immunostaining, Software, Microscopy, Cell Culture

Journal: Cell

Article Title: Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

doi: 10.1016/j.cell.2021.11.017

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: MK-1775 (Adavosertib) , Selleck Chemicals , Cat# S1525.

Techniques: Polymer, Recombinant, Amplification, Reverse Transcription, Membrane, DNA Library Preparation, Picogreen Assay, Software, Imaging

Journal: bioRxiv

Article Title: Unlocking DNA Damage Sensitivity of Cancer Cells: The Potential of Splicing Inhibitors

doi: 10.1101/2023.10.08.561421

Figure Lengend Snippet: A – Dose-response curves from MTT assays of SKOV3 cells treated with a fixed concentration of pladienolide B (1.56 nM) and various concentrations of carboplatin, cisplatin, doxorubicin, etoposide, or gemcitabine simultaneously for 48 hours. DMSO was used as a control instead of pladienolide B. B – Dose-response curves from MTT assays of SKOV3 cells pretreated with 1.56 nM pladienolide B or DMSO (control) for different durations (0, 6, 9, 12, 24, 48, 72, or 96 hours) followed by treatment with different concentrations of cisplatin for 48 hours. C – CellEvent Caspase-3/7 Green Flow Cytometry Assay of SKOV3 cells after different types of treatment. “Pl-B + CP” - pretreatment with pladienolide B (1.56 nM, 48 hours) followed by treatment with cisplatin (10 µM, 24 hours); “CP” - pretreatment with DMSO (48 hours) followed by treatment with cisplatin (10 µM, 24 hours); “Pl-B” - pretreatment with pladienolide B (1.56 nM, 48 hours) followed by fresh medium without pladienolide B (24 hours); “DMSO” - pretreatment with DMSO (48 hours) followed by fresh medium without DMSO (24 hours). D – Dose-response curves from MTT assays of various cell lines (MESOV, OVCAR3, TOV112D, TOV21G, A2789, Hep G2, HEY, HT29, A549, ID8, MDA-MB-231) treated with a fixed concentration of pladienolide B (1.56 nM) and different concentrations of cisplatin simultaneously for 48 hours. DMSO served as the control instead of pladienolide B. Each data point in A, B, D represents mean values ± SD (n = 3). IC50 values were determined by fitting a normalized model to data with nonlinear regression using GraphPad Prism software. Significance assessed via a paired, two-tailed Student’s t-test.

Article Snippet: Human ovarian cancer cell line OVCAR3 (ATCC, HTB-161) and murine colon carcinoma cell line CT26 (ATCC, CRL-2638) were grown in RPMI medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. hTERT-immortalized cells that were isolated from the fallopian tube of a female donor FT282 (ATCC, CRL-3449) was grown as adherent monolayers in DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin.

Techniques: Concentration Assay, Control, Flow Cytometry, Software, Two Tailed Test

Journal: bioRxiv

Article Title: Unlocking DNA Damage Sensitivity of Cancer Cells: The Potential of Splicing Inhibitors

doi: 10.1101/2023.10.08.561421

Figure Lengend Snippet: A – Dose-response curves from MTT assays of various cell lines (MESOV, OVCAR3, TOV112D, TOV21G, A2780, Hep G2, HEY, HT29, A549, ID8, MDA-MB-231) pretreated with 1.56 nM pladienolide B (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. DMSO was used as the control instead of pladienolide B. B – Dose-response curves from MTT assays of human primary fibroblasts pretreated with 1.56 nM pladienolide B (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. C – Dose-response curves from MTT assays of FT282 cells pretreated with 1.56 nM pladienolide B (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. D-E – Dose-response curves from MTT assays of pladienolide B-resistant SKOV3 cells treated with different concentrations of pladienolide B (D) or cisplatin (E) for 48 hours. The method for generating resistant SKOV3 cells is described in the “Methods” section. F – Dose-response curves from MTT assays of SKOV3 cells treated with different concentrations of H3B-8800 (another splicing inhibitor) for 48 hours. G – Dose-response curves from MTT assays of SKOV3 (red line) and cisplatin-resistant SKOV3 (light red line) cells treated with different concentrations of cisplatin for 48 hours. H – Dose-response curves from MTT assays of cisplatin-resistant SKOV3 cells pretreated with 1.56 nM pladienolide B (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. I – Dose-response curves from MTT assays of SKOV3 cells pretreated with 50 nM H3B-8800 (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. J-K – Synergy landscapes for SKOV3 (J) and A549 (K) cells after simultaneous or sequential treatment with different doses of DMSO (y-axis) and cisplatin (x-axis). Zero-Interaction Potency (ZIP) synergy scores were calculated for the combination of DMSO in different volume range (according to Pl-B volume for 0 nM–6.24 nM concentration range) and cisplatin (0 µM–80 µM) for SKOV3 and A549 cells. For simultaneous regimen, сells were treated with DMSO and cisplatin simultaneously (48 hours). For sequential regimen, cells were pretreated with different volumes of DMSO (48 hours) followed by treatment with different concentrations of cisplatin for 48 hours. Cell survival was calculated in comparison to cisplatin untreated cells (DMSO only). ZIP values below 0 indicate antagonism (blue), 0 - 10 indicate additivity (from white to light red), and above 10 (corresponding to a deviation from the reference model above 10%) indicate synergy (dark red). L-M – Synergy landscapes for HepG2 (L) and HT29 (M) cells. Each data point represents mean values ± SD (n = 3). IC50 values were determined by fitting a normalized model to data with nonlinear regression using GraphPad Prism software.

Article Snippet: Human ovarian cancer cell line OVCAR3 (ATCC, HTB-161) and murine colon carcinoma cell line CT26 (ATCC, CRL-2638) were grown in RPMI medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. hTERT-immortalized cells that were isolated from the fallopian tube of a female donor FT282 (ATCC, CRL-3449) was grown as adherent monolayers in DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin.

Techniques: Control, Concentration Assay, Comparison, Software